Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Tolerogenic RNA nanoparticles to treat autoimmunity
FY 2020-21
Summary
Multiple sclerosis (MS) is characterized by the dysregulation of multiple immunity-related genes, which results in the body's inability to tolerate the myelin proteins sheathing its nerves. The outcome is an immune system attack on the nerves and patient debilitation. A potential treatment for MS and other autoimmune diseases is to replenish regulatory T cells (Tregs), a subset of lymphocytes that maintain immune tolerance to self-proteins. Adoptive transfer of Tregs is promising to treat MS, but cell therapies have significant manufacturing and regulatory challenges, hence the importance of developing therapeutic options to induce Tregs in vivo. Current tolerogenic therapies fall short of successfully treating this autoimmune disease. Since each patient has a distinct disease signature, the lasting induction of Tregs requires a personalized therapy that can re-engineer the immune response and restore tolerance. We propose a ribonucleic acid (RNA)-based nanotechnology to treat this complex disorder. Our objective is to develop a non-immunogenic nanoparticle capable of delivering RNA combinations that expand antigen-specific Tregs. The payload includes the genetic code of the antigen requiring tolerance along with instructions to modulate the phenotype of immune cells. We hope to determine whether this unique nanotechnology can treat MS, thus paving the way for new curative treatments against MS and other autoimmune diseases.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449544
Name
Couture-Senécal Julien
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Tolerogenic RNA nanoparticles to treat autoimmunity
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigen Presenting Cells; Autoimmunity; Cytokines; Immune Tolerance; Intramuscular Injection; Multiple Sclerosis; Nanomaterials; Polymer; Regulatory T Cells; Ribonucleic Acid
Abstract
Multiple sclerosis (MS) is characterized by the dysregulation of multiple immunity-related genes, which results in the body's inability to tolerate the myelin proteins sheathing its nerves. The outcome is an immune system attack on the nerves and patient debilitation. A potential treatment for MS and other autoimmune diseases is to replenish regulatory T cells (Tregs), a subset of lymphocytes that maintain immune tolerance to self-proteins. Adoptive transfer of Tregs is promising to treat MS, but cell therapies have significant manufacturing and regulatory challenges, hence the importance of developing therapeutic options to induce Tregs in vivo. Current tolerogenic therapies fall short of successfully treating this autoimmune disease. Since each patient has a distinct disease signature, the lasting induction of Tregs requires a personalized therapy that can re-engineer the immune response and restore tolerance. We propose a ribonucleic acid (RNA)-based nanotechnology to treat this complex disorder. Our objective is to develop a non-immunogenic nanoparticle capable of delivering RNA combinations that expand antigen-specific Tregs. The payload includes the genetic code of the antigen requiring tolerance along with instructions to modulate the phenotype of immune cells. We hope to determine whether this unique nanotechnology can treat MS, thus paving the way for new curative treatments against MS and other autoimmune diseases.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Couture-Senécal, Julien
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~